Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity. Biomarkers are measurements based on molecular p...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2002-01-01
|
| Series: | Disease Markers |
| Online Access: | http://dx.doi.org/10.1155/2002/438745 |